Friend murine leukemia virus (FMuLv) is an acutely oncogenic retrovirus, and its infection leads to erythroblastosis and leukemia in mice. This infection model is used in the search for new antiviral agents. In the present study, the authors have evaluated the potential of an extract of Phyllanthus amarus against FMuLv-induced erythroleukemia in BALB/c mice. Injection of newborn mice with FMuLv resulted in leukemia and animals died due to splenomegaly. Oral administration of P.amarus was found to enhance the life span of leukemia-harboring animals and decrease the incidence of anemia. The authors also performed a series of hematological, biochemical, histopathological, and gene expression analyses to evaluate the effect of P.amarus administration on erythroleukemia initiation and progression. The data obtained indicate that P.amarus administration could significantly decrease the progression of erythroleukemia. Treatment with P.amarus induced the expression of p53 and p45NFE2 and decreased the expression of Bcl-2 in the spleen of infected mice. Histopathological evaluations of the spleen demonstrated that administration of P.amarus decreased the infiltration of leukemic cells into the sinusoidal space when compared with the vehicle treated group. P.amarus is known to inhibit chemically induced neoplasm in different rodent models. The current results indicate that P.amarus has the ability to suppress virally induced cancers as well.
Nearly 15% of all malignant tumors in humans have been linked with viral etiology. 1 A clear understanding of the possible mechanisms through which these viruses induce cellular transformation will be highly helpful in designing agents that can inhibit the growth of these viruses. 2 The erythroleukemia induced by Friend murine leukemia virus (FMuLv) is one of the best animal models available to study stepwise leukemia progression due to the reproducibility of the sequential genetic mutations leading to transformation of infected erythroblasts. 3 Moreover, this model has provided deep insights into the role of critical oncogenes involved in leukemia, in understanding the involvement of cellular machinery in the tumor development, and also helped in the screening of compounds as antiviral and anticancer agents. 4 The various mechanisms involved in the stepwise progression into erythroleukemia after infection with FMuLv is still an active area of research. [4] [5] [6] Infection with FMuLv is used as the retrovirus infection model for assessing the potential of medicinal preparations or establishing new treatment strategies. Therefore, the FMuLv-induced leukemia model is used in the development of antiviral agents useful in the inhibition of those cancers where viruses play a pivotal carcinogenic role.
Phyllanthus amarus Schum. & Thonn. (Family Phyllanthaceae) is well known for its antiviral effects. It has been reported to inhibit the production of hepatitis B surface antigen gene expression in human hepatoma cells. 7 P.amarus also inhibited the hepatitis B virus (HBV) mRNA transcription and replication, and Ott et al 8 demonstrated that P.amarus disrupts the interaction between HBV enhancer I and cellular transcription factors, thereby suppressing the HBV mRNA transcription. P.amarus also suppresses the growth of HIV in vitro as well as in vivo. 9 Related species such as P. niruri, P. myrtifolius, P. urinaria, and P. orbicularis have also been shown to inhibit the growth and replication of several viruses affecting human populations. 10, 11 Moreover, reports from our laboratory as well as by others showed that administration of P.amarus inhibited several types of tumors in different organs induced by a variety of chemicals in rodent models. 12,13 P.amarus also inhibited the activation of cytochrome P450 enzymes, thereby preventing the activation of carcinogens. 14 P.amarus also affords protection against radiotherapy-induced 15, 16 and chemotherapy-induced toxicities in mice. 17 In the present study, we have evaluated the efficacy of P.amarus on virally induced carcinogenesis in mice. Additionally, we also evaluated the effect of P.amarus administration on several biomarkers during tumorigenesis. The collective results indicated that P.amarus is effective in inhibiting the Friend virus-induced erythroleukemia in mice.
Materials and Methods

Animals and Virus
Newborn BALB/c mice (>15 hours old) were supplied from the animal house of Amala Cancer Research Centre. Animals were housed in well-ventilated polypropylene cages under controlled temperature (22°C to 25°C) and humidity (60% to 80%) and a light-dark cycle of 12 hours. They were provided with normal pelleted mice chow (Sai Durga Feeds and Foods, Bangalore, India) and water ad libitum. Animal experiments were conducted after obtaining prior permission from the Institutional Animal Ethics Committee and as per the instructions prescribed by the Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Environment and Forest, Government of India. The FMuLv-producing cell line Clone B was a kind gift from Dr Yaacov Ben-David, University of Toronto, Canada. It was maintained in RPMI 1640 (Hi-Media, Mumbai, India) medium with 10% FCS (Biological Industries, Beit Haemek, Israel) and antibiotics.
Preparation of P.amarus Extract
Seventy-five percent methanolic extract of P.amarus was prepared as described previously. 15 
Experimental Design for Erythroleukemia
FMuLv was isolated from the supernatant of Clone B fibroblast cell line as described earlier. 18 Newborn BALB/c mice (<15 hours old) were injected (intraperitoneal route, single dose) with 100 µL of the virus suspension (500 foci forming units) using 1-cm 3 U-40 insulin syringe (Dispovan, Delhi, India). Two weeks after the FMuLv injection, the animals were randomly divided into the following groups, each with 15 mice except for group I, which had 5 animals: (I) normal without any treatment, (II) injected with FMuLv and treated with vehicle (distilled water), (III) FMuLv + P.amarus 250 mg/kg body weight, and (IV) FMuLv + P.amarus 750 mg/kg body weight. The doses of P.amarus were decided on the basis of previous reports published on P.amarus from our laboratory. The extract was administered orally (once daily) starting from the 14th day after the viral inoculation and stopped at day 70, and thereafter animals were kept under observation. Five animals from each of groups II to IV were sacrificed on day 90 and whole necropsy performed. The rest of the animals were kept for the determination of life span.
Parameters Evaluated
Blood sampling and assay of hematological parameters. Blood was collected from the caudal vein of each mouse into heparinized tubes, and hematological parameters such as total red blood cell count (RBC) count, total white blood cell (WBC) count, and levels of hemoglobin were determined at day 90 after viral inoculation. The blood was smeared on a clean slide and stained by the periodic acid-Schiff (PAS) method, which specifically stains leukemic cells.
Body weight and life span. Body weights of all the animals were recorded on every 30th day. Life span of leukemiaharboring animals was also monitored.
Serum uric acid levels. Blood was collected through heart puncture, and levels of uric acid were estimated in the serum by a commercially available kit (Span Diagnostics, Surat, India). Histopathological analysis. The liver and spleen from the animals were excised and fixed in 10% buffered formalin. Five-micrometer-thick sections of paraffin-embedded tissues were made and stained using hematoxylin-eosin and observed under a microscope.
Gene expression analysis. To assess the effect of P.amarus administration during FMuLv-induced leukemia, we performed expression analysis of a selected panel of genes in the spleen. The RNA was isolated by the guanidinium thiocyanate method as described earlier. 19 Equal amounts of RNA were reverse transcribed into cDNA using oligo (dT) primers. The cDNA was prepared from the RNA by reverse transcriptase polymerase chain reaction (RT-PCR) and was used for the amplification of genes.
The oligonucleotide primers for PCR were purchased from Maxim Biotech (San Francisco, CA). The housekeeping gene GAPDH was used as an internal control. PCR primer sequences used in the study have been described elsewhere. 3 
Statistical Analysis
Data are presented as means and standard deviations. For statistical significance the independent variables were control or P.amarus treated or both depending on the value being compared (ie, a series of 1-way or 2-way analysis of variance models were fitted).
Results
Effect of P.amarus Administration on Survival, Body Weight, and Hematological Parameters
There was no immediate mortality after the injection of FMuLv to newborn BALB/c mice. In the control group (administered with vehicle only) 9 out of the 10 animals died. By the 120th day after viral inoculation the administration of P.amarus was found to significantly enhance the life span of erythroleukemia-harboring animals. The survival pattern of leukemia-bearing animals treated with P.amarus is given in Figure 1 . It was also noticed that the control animals showed symptoms of anemia starting from the 30th day after the FMuLv injection. Moreover, there was a decrease in the body weight of all the animals injected with FMuLv when compared with the normal (untreated) animals ( Table 1 ). The mice in the control group had a mean body weight of 13.39 ± 1.86 g whereas normal animals had a mean body weight of 22.64 ± 2.01 g on day 30. The treatment of P.amarus was found to increase the body weight with respect to the control group. The hemoglobin content also showed a decrease, indicating the persistence of anemia in FMuLv-treated animals. The control animals had a very low level of hemoglobin, which was 8.11 ± 1.07 g/dL on day 90 after treatment with vehicle. Hemoglobin values below 7 are generally regarded as indicating an anemic condition. The treatment with P.amarus was shown to increase the hemoglobin levels. The hemoglobin levels of all the groups are shown in Table 2 . The RBC count showed a slight decrease in control animals, whereas the WBC count remained constant without any significant changes. The slides prepared from all the FMuLv-injected animals after PAS staining showed typical leukemic cells in red color. The positive PAS staining confirmed the induction of leukemia by FMuLv. Treatment with P.amarus was effective in decreasing the number of PAS-stain-positive cells when compared with the control animals ( Figure 2A) . The blood smears also showed RBCs with deficiency in the hemoglobin content, further supporting our observation that FMuLv-induced erythroleukemia results in the anemic condition.
Effect of P.amarus Administration on Spleen Size and Serum Uric Acid Levels
The spleen of the control animals showed massive enlargement in size and shape ( Figure 2B ). The average weight of FMuLv spleen was 1.98 ± 0.12 g, whereas the average weight of the spleen of the normal mice was 0.30 ± 0.002 g. The treatment with P.amarus was found to decrease the spleen weight ( Figure 2C ). The serum uric acid levels were found to increase in all the leukemia-bearing animals. In control groups, it was elevated to 11.68 ± 1.47 mg/dL, whereas the normal level of uric acid in serum was 2.94 ± 0.82. The treatment with P.amarus was found to decrease the elevated uric acid levels (Figure 3 ).
Histopathological Evaluation of the Liver and the Spleen
We also performed the histological evaluation of the liver and the spleen from each group ( Figure 2D) . Hematoxy lin and eosin-stained paraffin-embedded liver sections showed normal architecture in all the groups. The portal areas, the space of Disse, sinusoidal spaces, endothelial cell population in the sinusoidal wall, Kupffer cells, and central venous system appeared to be normal. The paraffin-embedded sections of the spleen from the control (vehicle treated) animals showed hyperplastic lymphoid follicles. Subcapsular sinus and sinusoidal spaces were filled with pleomorphic round or oval cells having the features of blast cells. Many degenerating cells and mitotic cells were also present. Focal areas of hemorrhage and necrosis were present. The cellularity of the spleenic white pulp was increased along with expansion of red pulp. Presence of erythroid progenitor cells was at different stages of development. The sections showed massive leukemic cell infiltration to sinusoidal spaces. In the P.amarus-treated group when compared with the control group these pathological changes were not significant. The numbers of infiltrating leukemic cells into the sinusoidal space were less in number. The number of mitotic cells was low. All the observations indicate that P.amarus was effective in decreasing the progression of leukemia.
Effect of P.amarus Treatment on Gene Expression Profile
The antiapoptotic gene Bcl-2 was overexpressed in control (vehicle treated), and treatment with P.amarus was found to inhibit the overexpression of Bcl-2 (Figure 4) . The tumor suppressor gene p53 was completely lost in the control groups, and we observed that P.amarus administration induced the expression of p53. p45NFE2, a negative regulator of erythroid differentiation, was completely lost in the control group. P.amarus treatment also resulted in the expression of p45NFE. Thus, P.amarus treatment inhibited the expression of Bcl-2 and induced the expression of p53 as well as p45NFE, which possibly might have resulted in the inhibition of progression of leukemia. The expression of erythropoietin, a hematopoietic cytokine that regulates erythrocyte production, was found in all the groups and higher expression was found in the control group. P.amarus administration was not effective in completely suppressing the expression of erythropoietin. Raf-1 and Erk-1 were present in all the groups but the rate of expression was high in control groups. The Raf-1/ERK-1 pathway plays an active role in the FMuLv-induced transformation. The interferon-γ receptor expression, which is essential for the binding of interferon and interferon mediated signaling, was high in control groups.
Discussion
Erythroleukemia falls under the category of acute myeloid leukemia (AML), and according to the French-American-British system, erythroleukemia is the M6 subtype of AML. It is now known that the induction and progression of erythroleukemia by Friend virus are mainly due to the ability of proviruses to activate the cellular protooncogenes or inactivate the tumor suppressor genes. Proviral integration eventually leads to the dysregulated expression of several genes whose products are involved in several cellular processes such as growth, cell division, and cell death. Moreover, the process of leukemogenesis in Friend virus in murine models is initiated from an acute hyperplasia of erythroid progenitor cells followed later on by a blastic crisis. In fact, these mouse erythroleukemia models resemble the 2 phases of human AML due to their multistep evolution. In the present study, we have found that infection of newborn BALB/c mice with FMuLv resulted in erythroleukemia. All the infected animals developed the tumor. The control animals died by the 120th day, and the administration of P.amarus significantly increased the life span of leukemiabearing animals. The anemic condition was also reduced by the treatment with P.amarus. The analysis of serum biomarker levels and histopathological evaluation of tissues further support the observation that P.amarus reduced tumor incidence and increased the life span of tumor-bearing animals.
We also performed gene expression analysis of a selected panel of genes during the progression of leukemia. In FMuLvinduced leukemia there was overexpression of Bcl-2 during the progression stage. 20 We found that P.amarus inhibited the expression of antiapoptotic gene Bcl-2. P.amarus is also known to inhibit the expression of Bcl-2 in other tumor types such as Dalton's lymphoma ascites cells.
The expression of p45NFE2 is highly tissue specific. Erythrocytes, mast cells, and megakaryocytes show the expression of p45NFE2, which is a negative regulator of erythroid proliferation, and it was reported by several workers that this gene is generally lost during the progression of erythroleukemia. 21 P.amarus treatment resulted in the induction of this gene. Our data also indicated that P.amarus treatment induced the expression of p53. The treatment of the extract resulted in the inhibition of antiapoptotic Bcl-2 and induction of p53 and p45NFE2, which act as negative regulators of erythroid cell proliferation, leading to the inhibition of progression of leukemia.
The envelope protein of Friend virus binds with the erythropoietin (Epo) receptor and induces Epo-mediated cell proliferation. 22 The expression of Epo in FMuLv-induced erythroleukemic cell lines establishes an autocrine loop that results in a constitutive activation of a signal transduction cascade mediated by the Epo receptor. This constitutive activation confers a selective growth advantage to these erythroleukemic cells both in vitro as well as in vivo. We found that P.amarus inhibited the Epo expression; however, we could not observe a complete inhibition of Epo expression. A similar observation was noted with the expression of Raf-1 and Erk-1. The ERK pathway is constitutively active in Friend virus-induced leukemia. The treatment with P.amarus was effective in decreasing the expression of these genes. These results further support the protective effect of P.amarus in erythroleukemia.
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